Dendreon: An Even Better Risk vs. Reward Scenario - Seeking Alpha

"Lets Be Reasonable submits: In my April 23rd article, 'Dendreon: Revisiting the Risk/Reward Scenario', I noted that at $15, there was $2 to $3 of downside risk for Dendreon (DNDN), with possibly $15 to $20 of upside. Given a 50/50 chance of FDA approval, I fully expected the stock price to rebound and trade in the $21 to $24 range as the May 15 date approaches."